American Health Intel Rules. Money. Medicine. Decoded daily.
Subscribe
← All editions
Following a story · 2 updates

Medicare GLP-1 Bridge program reaches roughly 600,000 enrollees by end of August, about 15% of eligible beneficiaries

Sep 12, 2026 – Sep 26, 2026

  1. Sep 12, 2026 The Service Line Rule

    Medicare GLP-1 Bridge demonstration live since July 1 with $50 monthly copay and no published enrollment data

    CMS's GLP-1 Bridge demonstration went live July 1, 2026, covering Wegovy, Zepbound, and Foundayo at a flat $50 monthly copay for qualifying Medicare Part D enrollees through December 31, 2027, while CMS has not released any uptake figures and FDA has not yet finalized a rule barring large-scale compounding of semaglutide and tirzepatide.

    Read this issue →
  2. Sep 26, 2026 The Service Line Report Latest

    Medicare GLP-1 Bridge program reaches roughly 600,000 enrollees by end of August, about 15% of eligible beneficiaries

    CMS confirmed at an August 31 briefing that enrollment in the GLP-1 Bridge demonstration reached approximately 600,000 Medicare beneficiaries, up from about 250,000 in July, covering obesity-diagnosed enrollees who receive Wegovy, Zepbound, or Foundayo at a $50 monthly copay, while an estimated 5.9 million additional Medicare enrollees with GLP-1-relevant diagnoses remain on standard Part D cost sharing.

    Read this issue →